# Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection

> **NCT03853369** · — · UNKNOWN · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 2000 (estimated)

## Conditions studied

- Ventricular Tachycardia
- Ventricular Fibrillation

## Interventions

- **DRUG:** Nifekalant hydrochloride

## Key facts

- **NCT ID:** NCT03853369
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-18
- **Primary completion:** 2019-12-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2019-03-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03853369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03853369, "Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03853369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*